Total Funding
1
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
4289730
Crucell researches and develops products and markets vaccines, proteins and antibodies for the treatment of infectious diseases.
Acquired by 
Johnson & Johnson
William Burns: Member of the Supervisory Board at Crucell Sweden ABPast Role: Roche Holdings, Australia, Chief Executive Officer of Pharmaceuticals Division
About the Company
Crucell N.V. is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid
vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market.
